62567-44-6

Basic information

• Product Name: 3-Ethoxypyridazine
• Synonyms: Pyridazine, 3-ethoxy-
• CAS NO: 62567-44-6
• Molecular Formula: C₆H₈N₂O
• Molecular Weight: 124.14052
• Mol File: 62567-44-6.mol
• Article Data: 4

Chemical Properties

• Melting Point: 35-36 °C
• Boiling Point: 69-71 °C(Press: 2-3 Torr)
• Appearance: /
• Density: 1.066±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.29±0.10(Predicted)
• CAS DataBase Reference: 3-Ethoxypyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Ethoxypyridazine(62567-44-6)
• EPA Substance Registry System: 3-Ethoxypyridazine(62567-44-6)

Safety Data

• Hazardous Substances Data: 62567-44-6(Hazardous Substances Data)

Usage

General Description

3-Ethoxypyridazine is a chemical compound that belongs to the class of organic compounds known as pyridazines and derivatives. These are compounds containing a pyridazine ring, which is a six-membered aromatic ring with two nitrogen atoms at positions 1 and 2, and four carbon atoms. 3-Ethoxypyridazine is a relatively neutral molecule with molecular formula C7H9N2O. It has a distinctive aromatic odor and is generally used as a reagent in organic synthesis. Due to its reactive properties, it's commonly used to design and prepare more complex chemical structures, including pharmaceuticals.

Upstream product

• 1120-95-2 3-chloropyridazine 
• 141-52-6 sodium ethanolate 
• 17321-20-9 3-chloro-6-(ethyloxy)pyridazine 

Downstream Products

• 748141-86-8 1-[6-(ethyloxy)pyrazolo[1,5-b]pyridazin-3-yl]ethanone 
• 504-30-3 2H-Pyridazin-3-one 

Relevant articles and documents

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

N-phenyl-4-pyrazolo[1,5-6]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy

Glycogen synthase kinase 3 regulates glycogen synthase, the rate-determining enzyme for glycogen synthesis. Liver and muscle glycogen synthesis is defective in type 2 diabetics, resulting in elevated plasma glucose levels. Inhibition of GSK-3 could potentially be an effective method to control plasma glucose levels in type 2 diabetics. Structure-activity studies on a N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine series have led to the identification of potent and selective compounds with good cellular efficacy. Molecular modeling studies have given insights into the mode of binding of these inhibitors. Since the initial leads were also potent inhibitors of CDK-2/CDK-4, an extensive SAR was performed at various positions of the pyrazolo[1,5-b] pyridazin core to afford potent GSK-3 inhibitors that were highly selective over CDK-2. In addition, these inhibitors also exhibited very good cell efficacy and functional response. A representative example was shown to have good oral exposure levels, extending their utility in an in vivo setting. These inhibitors provide a viable lead series in the discovery of new therapies for the treatment of type 2 diabetes.